The overall objective of the Case Gl Cancer SPORE Developmental Research Program (SDRP) is to develop innovative and diverse approaches to focus on Gl Cancer translational research across the spectrum from etiology through prevention screening, diagnostics, therapeutics, and survivorship. The SPORE Developmental Research Program will provide 1) financial support, 2) Core Facility Services and 3) intellectual oversight and advice for pilot research projects and investigators. Emphasis will be placed on supporting new investigators as well as established investigators with new approaches to Gl cancers. To stimulate translational research, pilot projects with 2 Co-PI's, one basic and one clinical investigator, will be given preference. For meritorious proposals from individual basic or clinical investigators, the SDRP leadership group will identify complementary translational investigators to serve as advisors. Special plans will be instituted to stimulate Gl cancer research in new areas other than colorectal cancer. The Case Gl SPORE considers the pilot project mechanism to be an important opportunity for initiation of high risk/high impact research and will accordingly provide appropriate prioritization for such proposals. With support from the Case School of Medicine, The Case Comprehensive Cancer Center and SPORE Funds, the SDRP will support up to 4 pilot projects per year at $50,000 each. Availability of pilot projects will be announced by multiple, institution wide, electronic notice systems, by direct communication with department heads and deans and by invitations to specific scientists with exciting new approaches. Pilot proposals will be evaluated using the NIH 9 point scoring system by the SDRP Evaluation Panel composed of selected series of faculty members with involvement in Gl Cancer Research and extensive experience in NIH and other national organization peer review study sections.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Venkitachalam, Srividya; Guda, Kishore (2017) Altered glycosyltransferases in colorectal cancer. Expert Rev Gastroenterol Hepatol 11:5-7
Arif, Abul; Terenzi, Fulvia; Potdar, Alka A et al. (2017) EPRS is a critical mTORC1-S6K1 effector that influences adiposity in mice. Nature 542:357-361
Morris, Shelli M; Davison, Jerry; Carter, Kelly T et al. (2017) Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factor-beta signaling in mouse intestinal neoplasms. Int J Cancer 140:853-863
Cummings, Linda C; Thota, Prashanthi N; Willis, Joseph E et al. (2017) A nonrandomized trial of vitamin D supplementation for Barrett's esophagus. PLoS One 12:e0184928
Hu, Xiao; He, Yanhua; Wu, Liping et al. (2017) Novel all-hydrocarbon stapled p110?[E545K] peptides as blockers of the oncogenic p110?[E545K]-IRS1 interaction. Bioorg Med Chem Lett 27:5446-5449
Zhao, Yiqing; Scott, Anthony; Zhang, Peng et al. (2017) Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis. Oncotarget 8:48782-48793
Luebeck, E Georg; Curtius, Kit; Hazelton, William D et al. (2017) Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma. Clin Epigenetics 9:113
Petersen, Christine P; Meyer, Anne R; De Salvo, Carlo et al. (2017) A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut :
Kim, Jaeil; Do, Eun-Ju; Moinova, Helen et al. (2017) Molecular Imaging of Colorectal Tumors by Targeting Colon Cancer Secreted Protein-2 (CCSP-2). Neoplasia 19:805-816
Cohen, Andrea J; Saiakhova, Alina; Corradin, Olivia et al. (2017) Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nat Commun 8:14400

Showing the most recent 10 out of 127 publications